B. Riley Has Pessimistic Outlook of Geron FY2025 Earnings

Geron Co. (NASDAQ:GERN) – B. Riley dropped their FY2025 earnings per share (EPS) estimates for Geron in a research report issued to clients and investors on Tuesday, February 18th. B. Riley analyst K. Patel now expects that the biopharmaceutical company will post earnings per share of ($0.08) for the year, down from their previous forecast of ($0.03). B. Riley has a “Buy” rating and a $3.50 price target on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share. B. Riley also issued estimates for Geron’s FY2026 earnings at $0.12 EPS.

Several other research analysts also recently weighed in on the stock. Needham & Company LLC upped their price target on shares of Geron from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Monday, January 13th. Barclays upgraded Geron to a “strong-buy” rating in a research report on Friday, November 29th. Finally, HC Wainwright reiterated a “buy” rating and set a $9.00 price target on shares of Geron in a research report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $6.91.

Geron Stock Performance

GERN opened at $2.62 on Thursday. The firm has a fifty day moving average price of $3.13 and a 200 day moving average price of $3.88. Geron has a 1 year low of $1.64 and a 1 year high of $5.34. The stock has a market cap of $1.58 billion, a P/E ratio of -8.17 and a beta of 0.53. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. RTW Investments LP acquired a new stake in Geron during the third quarter worth $200,268,000. Vanguard Group Inc. increased its position in shares of Geron by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 33,538,822 shares of the biopharmaceutical company’s stock worth $118,727,000 after purchasing an additional 1,088,912 shares during the last quarter. State Street Corp raised its holdings in Geron by 28.4% in the 3rd quarter. State Street Corp now owns 28,961,671 shares of the biopharmaceutical company’s stock valued at $131,486,000 after buying an additional 6,413,204 shares during the period. Janus Henderson Group PLC lifted its position in Geron by 20.0% in the fourth quarter. Janus Henderson Group PLC now owns 27,082,461 shares of the biopharmaceutical company’s stock valued at $95,769,000 after buying an additional 4,516,615 shares during the last quarter. Finally, Holocene Advisors LP purchased a new position in Geron during the third quarter worth about $82,498,000. 73.71% of the stock is currently owned by institutional investors and hedge funds.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.